1.Clinical study on transcatheter arterial chemoembolization for hepatic carcinoma in radial artery ;access
Feng CHEN ; Ning WU ; Sirui LI ; Fuhuang LIN
Journal of Interventional Radiology 2014;(5):435-437
Objective To explore the clinical value of transarterial chemoembolization (TACE) for hepatic carcinoma in radial artery access. Methods From Octomber 2012 to June 2013, 15 patients with liver cancer were treated with transarterial chemoembolization via radial artery access. Results 13 cases were treated successfully via the radial artery access. One case were failed for vasospasm when puncturing left radial artery and successed via homolateral ulnar artery access. 1 case with supraclavicular lymph node metastasis received interventional therapy via right radial artery access. Conclusion The technic of transarterial chemoembolization via radial artery is safe, efficient and has fewer complications and suffering to patients.
2.Single-nucleotide polymorphisms in DNA repair genes APE1 and XRCC1 and suscep-tibility to hepatocellular carcinoma and their correlation with sensitivity of platinum chemotherapy in HCC
Zhuangwei FANG ; Zhu LIANG ; Ning WU ; Chun QIU ; Fuhuang LIN ; Bo YUAN ; Yonghong PENG ; Yong FU ; Weiping ZHOU ; Kailun ZHOU ; Xianhe XIE
Military Medical Sciences 2014;(1):48-52
Objective To investigate the relationship between APE1, XRCC1 gene polymorphisms and hepatocellular carcinoma(HCC) susceptibility and to explore the correlation of APE1, XRCC1 gene polymorphisms with the sensitivity to platinum-based drugs .Methods Seventy-eight HCC patients and 80 controls were selected .By PCR and RFLP , the single nucleotide polymorphism of APE1 Asp148Glu and XRCC1 Arg194Trp genes and the susceptibility of HCC or platinum drug sensitivity were analyzed.Results The Glu/Glu genotype of APE1 could increase in the risk of HCC by 7.21 times (95%CI:1.325-29.109) (P<0.05).APE1 and XRCC1 gene polymorphisms could also affect the platinum drug resistance of HCC patients.Conclusion APE1 Asp148Glu is correlated with the susceptibility to HCC .APE1 and XRCC1 genes can be considered a target for therapy to improve the sensitivity of HCC platinum drugs .